Sub-Q Tocilizumab Gives Durable Long-Term Responses in JIA Sub-Q Tocilizumab Gives Durable Long-Term Responses in JIA
Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety concerns, in an LTE study of two trials.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 12, 2024 Category: Rheumatology Tags: Rheumatology Clinical Summary Source Type: news
Tocilizumab Withdrawal Post Remission in Still's Disease Tocilizumab Withdrawal Post Remission in Still's Disease
Longer tocilizumab administration intervals and lower prednisolone doses seemed pivotal for successful tocilizumab withdrawal while maintaining remission in patients with AOSD.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 11, 2024 Category: Allergy & Immunology Tags: Rheumatology Clinical Summary Source Type: news
FDA Approves Tyenne (tocilizumab-aazg), a Biosimilar to Actemra
March 7, 2024 -- Fresenius Kabi, a global health care company that specializes in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, announced today that the United States (U.S.)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 7, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Approves Second Tocilizumab Biosimilar FDA Approves Second Tocilizumab Biosimilar
Tocilizumab-aazg (Tyenne) is approved in both intravenous and subcutaneous formulations.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - March 7, 2024 Category: Internal Medicine Tags: Rheumatology Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
Diagnosing Infection in Tocilizumab Users: What's Helpful? Diagnosing Infection in Tocilizumab Users: What's Helpful?
Area under the curve for routine biomarkers distinguished infected and noninfected adults with inflammatory diseases.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 23, 2024 Category: Allergy & Immunology Tags: Rheumatology Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
Effective Treatments Identified for Pediatric Complication of COVID
(MedPage Today) -- PHOENIX -- First-line treatment with methylprednisolone and second-line treatment with tocilizumab (Actemra) shortened hospital stays for children with pediatric multisystem inflammatory syndrome temporally associated with... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - January 27, 2024 Category: Infectious Diseases Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Media News - December 19, 2023 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Investor Update - December 19, 2023 Category: Pharmaceuticals Source Type: news
Short Steroid Taper Tested With Tocilizumab for GCA Short Steroid Taper Tested With Tocilizumab for GCA
Results from a pilot study examining a shortened prednisone taper of 8 weeks ' length rather than 26 weeks suggest it may be possible to reduce patients ' duration of exposure to glucocorticoids.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 11, 2023 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Actemra Biosimilar Approved
(MedPage Today) -- The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (sJIA)... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 3, 2023 Category: Infectious Diseases Source Type: news
FDA Approves First Tocilizumab Biosimilar FDA Approves First Tocilizumab Biosimilar
Tocilizumab-bavi (Tofidence) will offer a lower-cost option for patients with autoimmune conditions, the drug manufacturer, Biogen, stated.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 29, 2023 Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Alert Source Type: news
